The leishmaniases.
D000578:Amidines / Q000627:therapeutic use; D000965:Antimony / Q000009:adverse effects / Q000627:therapeutic use; D002241:Carbohydrates / Q000627:therapeutic use; D006571:Heterocyclic Compounds / Q000627:therapeutic use; D006577:Heterocyclic Oxides / Q000627:therapeutic use; D006801:Humans; D007891:Leishmania / Q000378:metabolism / Q000502:physiology; D007896:Leishmaniasis / Q000188:drug therapy / Q000209:etiology / Q000473:pathology / Q000517:prevention & control; D009942:Organometallic Compounds / Q000009:adverse effects / Q000627:therapeutic use; D009626:Terminology as Topic
D000578:Amidines; D002241:Carbohydrates; D006571:Heterocyclic Compounds; D006577:Heterocyclic Oxides; D009942:Organometallic Compounds; D000965:Antimony